var data={"title":"Acebutolol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acebutolol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5548?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acebutolol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acebutolol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129226\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sectral [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129227\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Acebutolol&reg;;</li>\n      <li>Ava-Acebutolol;</li>\n      <li>Mylan-Acebutolol;</li>\n      <li>Mylan-Acebutolol (Type S);</li>\n      <li>Nu-Acebutolol;</li>\n      <li>Rhotral;</li>\n      <li>Sandoz-Acebutolol;</li>\n      <li>Sectral&reg;;</li>\n      <li>Teva-Acebutolol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129265\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Class II;</li>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Beta-Blocker With Intrinsic Sympathomimetic Activity;</li>\n      <li>\n        Beta-Blocker, Beta-1 Selective</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129230\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ventricular arrhythmia (eg, ventricular premature beats):</b> Oral: 400 mg daily in 2 divided doses; maintenance: 600 to 1,200 mg daily in divided doses; maximum: 1,200 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral: Initial: 400 mg in 1 to 2 divided doses; optimal response usually seen at 400 to 800 mg daily (larger doses may be divided) although some patients may respond to as little as 200 mg daily; usual dose range (ASH/ISH [Weber 2014]): 200 to 400 mg daily; maximum dose: 1,200 mg in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stable ischemic heart disease (off-label use):</b> Oral: Initial: 200 mg 3 times daily; titrated to desired heart rate by increasing at weekly intervals by 300 mg/day; maximum dose: 1,200 mg/day (DiBianco 1980; Lee 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxicosis (off-label use): </b>Oral: 200 mg 2 to 3 times daily; treatment period in clinical trials was 7 to 10 days (Jones 1981; Perret 1984; Perrild 1986). Additional data may be necessary to further define the role of acebutolol in the treatment of this condition. <b>Note:</b> Other beta blockers (eg, propranolol) may be preferred in this setting (ATA [Ross 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129231\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Consider dose reduction due to age-related increase in bioavailability; do not exceed 800 mg/day. In the management of hypertension, consider lower initial dose (eg, 200 to 400 mg/day) and titrate to response (Aronow, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129232\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl 25 to 49 mL/minute: Reduce dose by 50%. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &lt;25 mL/minute: Reduce dose by 75%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129233\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129199\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sectral: 200 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sectral: 400 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129183\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23610278\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sectral: 100 mg, 200 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129203\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129202\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypertension; management of ventricular arrhythmias (eg, ventricular premature beats)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8; James 2013]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;60 years of age with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg. Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &lt;60 years of age with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;18 years of age with diabetes and SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;18 years of age with chronic kidney disease (CKD) and SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">In patients with CKD, regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD), including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD), including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720646\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Thyrotoxicosis; Stable ischemic heart disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129272\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sectral may be confused with Seconal, Septra</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129190\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Fatigue (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (2%), edema (2%), bradycardia, cardiac failure, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (6%), headache (6%), insomnia (3%), abnormal dreams (2%), depression (2%), anxiety, hyperesthesia, hypoesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2%), pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (4%), diarrhea (4%), dyspepsia (4%), nausea (4%), flatulence (3%), abdominal pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary frequency (3%), dysuria, impotence, nocturia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (2%), arthralgia, back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (2%), conjunctivitis, dry eye syndrome, eye pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (4%), rhinitis (2%), cough (1%), pharyngitis, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anorexia, atrioventricular block, cold extremities, facial edema, hepatotoxicity, increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases, lichen planus, lupus-like syndrome, palpitations, pleurisy, pneumonitis, pulmonary granuloma, renal insufficiency, systemic lupus erythematosus, urinary retention, ventricular arrhythmia, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129206\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Overt cardiac failure; cardiogenic shock; persistently-severe bradycardia or second- and third-degree heart block (except in patients with a functioning artificial pacemaker)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129187\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; for patients with bronchospastic disease who do not respond to or cannot tolerate other therapies, initial low doses of acebutolol may be employed and used cautiously with close monitoring. Ensure patient has an inhaled beta<sub>2</sub>-agonist immediately available. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conduction abnormality: Consider preexisting conditions such as sick sinus syndrome before initiating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure (HF): Beta-blockers with intrinsic sympathomimetic activity (eg, acebutolol) are likely to worsen survival in patients with HF and should be avoided. Beta-blockers shown to improve survival in clinical trials should be used in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Mesenteric vascular disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with mesenteric vascular disease. Use with caution in these patients. Observe closely for progression of arterial obstruction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral vascular disease (PVD) and Raynaud's disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pheochromocytoma (untreated): Adequate alpha<sub>1</sub>-receptor blockade is required prior to use of any beta-blocker.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment, especially the elderly. Elimination of the metabolite, diacetolol, is reduced resulting in a two- to threefold increase in its half-life.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm. Alterations in thyroid function tests may be observed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use reduced doses in elderly patients; concentrations of acebutolol and diacetolol are significantly higher in the elderly. Dose should not exceed 800 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129260\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129192\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9233&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129221\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Peak serum acebutolol levels may be slightly decreased if taken with food. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129195\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129209\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in some animal reproduction studies. Acebutolol and diacetolol (active metabolite) cross the placenta. Decreases in birth weight, blood pressure, and heart rate have been observed in neonates following maternal use of acebutolol during pregnancy. Hypoglycemia has also been found following in utero exposure to beta-blockers as a class. The half-life of acebutolol is 6 to 14 hours in the newborn. The half-life of diacetolol is 24 to 30 hours for the first 24 hours of life, then 12 to 16 hours. Adequate facilities for monitoring infants at birth should be available. The plasma elimination half-life of acebutolol is longer in pregnant women at term (Bianchetti 1981a; Boutroy 1982).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension and preeclampsia are also associated with adverse events in the fetus, infant, and mother (ACOG 2015; Magee 2014). When treatment of hypertension in pregnancy is indicated, beta-blockers may be used. Specific recommendations vary by guideline. Although other agents are preferred (ACOG 2013), use of acebutolol may be considered (Magee 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129210\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Acebutolol and diacetolol (active metabolite) are excreted into breast milk. Bradycardia, hypotension, and tachypnea (transient) were observed in a nursing infant (Boutroy 1986). Breast-feeding is not recommended by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129211\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129197\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood glucose (especially in patients with diabetes mellitus); blood pressure, orthostatic hypotension, heart rate, CNS effects, ECG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129186\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively blocks beta<sub>1</sub>-adrenergic receptors with little or no effect on beta<sub>2</sub>-receptors except at high doses; exhibits membrane stabilizing and intrinsic sympathomimetic activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129205\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 40% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~26%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive first-pass effect to equipotent and cardioselective diacetolol metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Acebutolol: 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: 3 to 4 hours; Metabolite: 8 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (50% to 60%); urine (30% to 40%); diacetolol eliminated primarily in the urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129208\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Acebutolol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $100.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $133.97</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129212\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abutol (TW);</li>\n      <li>ACB (NZ);</li>\n      <li>Acecor (CZ);</li>\n      <li>Acepin (TW);</li>\n      <li>Acetanol (JP);</li>\n      <li>Beloc (CL);</li>\n      <li>Butobloc (ZA);</li>\n      <li>Diasectral (FI);</li>\n      <li>Flebutol (VE);</li>\n      <li>Gentolol (TW);</li>\n      <li>Grifobutol (CL);</li>\n      <li>Prent (CH, DE, IT, PT, TR);</li>\n      <li>Rhodiasectral (AR);</li>\n      <li>Sectral (AT, BB, BE, BM, BR, BS, BZ, CH, CZ, EG, FR, GB, GY, HK, IE, IL, IN, IQ, IR, IT, JM, JP, KR, LB, LU, LY, PL, SG, SR, SY, TT, TW, VN, YE, ZA);</li>\n      <li>Sectral LP (FR);</li>\n      <li>Sincer (TW);</li>\n      <li>Wesfalin (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice. Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/25611642 /pubmed\" target=\"_blank\" id=\"25611642 \">25611642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):1-157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/17692738/pubmed\" target=\"_blank\" id=\"17692738\">17692738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, Anbe DT, Armstrong PW, et al. &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo; <i>J Am Coll Cardiol</i>, 2004, 44(3):671-719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/15358045/pubmed\" target=\"_blank\" id=\"15358045\">15358045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bianchetti G, Boutroy MJ, Dubruc PL, et al, &quot;Placental Transfer and Pharmacokinetics of Acebutolol and N-acetyl Acebutolol in the Newborn. Communications,&quot; <i>Br J Pharmacol</i>, 1981, 72(1):135P&ndash;136P.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Becker DE, Reed KL. Essentials of local anesthetic pharmacology. <i>Anesth Prog.</i> 2006;53(3):98-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/17175824/pubmed\" target=\"_blank\" id=\"17175824\">17175824</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boutroy MJ, Bianchetti G, Dubruc C, et al, &quot;To Nurse When Receiving Acebutolol: Is it Dangerous for the Neonate?&quot; <i>Eur J Clin Pharmacol</i>, 1986, 30(6):737-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/3770068/pubmed\" target=\"_blank\" id=\"3770068\">3770068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boutroy MJ, Vert P, Bianchetti G, et al, &quot;Infants Born to Hypertensive Mothers Treated by Acebutolol. Pharmacological Studies in the Perinatal Period,&quot; <i>Dev Pharmacol Ther</i>, 1982, 4 Suppl:109-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/7128381/pubmed\" target=\"_blank\" id=\"7128381\">7128381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo; <i>Br J Dermatol</i>, 2008, 158(6):1299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/18410416/pubmed\" target=\"_blank\" id=\"18410416\">18410416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11281737\"></a>Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. <i>Ann Intern Med</i>. 2001;134(7):550-560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/11281737/pubmed\" target=\"_blank\" id=\"11281737\">11281737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. <i>Lancet</i>. 2002;359(9311):995-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/11937178/pubmed\" target=\"_blank\" id=\"11937178\">11937178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiBianco R, Singh S, Singh JB, et al. Effects of acebutolol on chronic stable angina pectoris. A placebo-controlled, double-blind, randomized crossover study. <i>Circulation</i>. 1980;62(6):1179-1187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/6777070/pubmed\" target=\"_blank\" id=\"6777070\">6777070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dumez Y, Tchobroutsky C, Hornych H, et al, &ldquo;Neonatal Effects of Maternal Administration of Acebutolol,&rdquo; <i>Br Med J (Clin Res Ed)</i>, 1981, 283(6299):1077-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/6794766/pubmed\" target=\"_blank\" id=\"6794766\">6794766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23166211\"></a>Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foster CA and Aston SJ, &ldquo;Propranolol-Epinephrine Interaction: A Potential Disaster,&rdquo; <i>Plast Reconstr Surg</i>, 1983, 72(1):74-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/6867180 /pubmed\" target=\"_blank\" id=\"6867180 \">6867180 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gandy W. Severe epinephrine-propranolol interaction. <i>Ann Emerg Med.</i> 1989;18:98-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/2910169/pubmed\" target=\"_blank\" id=\"2910169\">2910169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geffner DL and Hershman JM, &ldquo;beta-Adrenergic Blockade for the Treatment of Hyperthyroidism,&rdquo; <i>Am J Med</i>, 1992, 93(1):61-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/1352658/pubmed\" target=\"_blank\" id=\"1352658\">1352658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12570960\"></a>Gibbons RJ, Abrams J, Chatterjee K, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina),&rdquo; <i>J Am Coll Cardiol</i>, 2003, 41(1):159-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/12570960/pubmed\" target=\"_blank\" id=\"12570960\">12570960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons RJ, Chatterjee K, Daley J, et al, &ldquo;ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(7):2092-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/10362225/pubmed\" target=\"_blank\" id=\"10362225\">10362225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series. <i>J Am Dent Assoc.</i> 1999;130(3):397-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/10085663/pubmed\" target=\"_blank\" id=\"10085663\">10085663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>. 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones MK, Birtwell J, Owens DR, Jones GR, Lewis M. Beta-adrenoreceptor blocking drugs and thyroid hormones in hyperthyroid subjects. <i>Postgrad Med J</i>. 1981;57(666):207-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/6117063/pubmed\" target=\"_blank\" id=\"6117063\">6117063</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo; <i>Drug Saf</i>, 1995, 12(5):299-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/7669259/pubmed\" target=\"_blank\" id=\"7669259\">7669259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee G, DeMaria AN, Favrot L, et al. Efficacy of acebutolol in chronic stable angina using single-blind and randomized double-blind protocol. <i>J Clin Pharmacol</i>. 1982;22(8-9):371-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/6813360/pubmed\" target=\"_blank\" id=\"6813360\">6813360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/24927294 /pubmed\" target=\"_blank\" id=\"24927294 \">24927294 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mito RS, Yagiela JA. Hypertensive response to levonordefrin in a patient receiving propranolol: report of a case. <i>J Am Dent Assoc.</i> 1988;116(1):55-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/3278028/pubmed\" target=\"_blank\" id=\"3278028\">3278028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perret G, Hugues JN, Modigliani E, Sebaoun J. Compared effect of propranolol and acebutolol on serum thyroid hormones' levels in euthyroid and hyperthyroid patients: a randomized study. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1984;22(7):360-364.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/6469425/pubmed\" target=\"_blank\" id=\"6469425\">6469425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrild H, Feldt-Rasmussen U, Kayser L, M&oslash;lholm Hansen J. Short-term beta-adrenergic blockade decreases serum thyroglobulin in hyper- and euthyroid patients. <i>J Endocrinol Invest</i>. 1986;9(5):413-415.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/2878948/pubmed\" target=\"_blank\" id=\"2878948\">2878948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pi&ntilde;a IL, Smith EV, and Weidler DJ, &ldquo;Low-dose Acebutolol Given Once Daily in the Treatment of Chronic Angina Pectoris,&rdquo; <i>J Clin Pharmacol</i>, 1988, 28(5):427-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/3392240/pubmed\" target=\"_blank\" id=\"3392240\">3392240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryan TJ, Anderson JL, Antman EM, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction),&rdquo; <i>J Am Coll Cardiol</i>, 1996, 28(5):1328-428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/8890834/pubmed\" target=\"_blank\" id=\"8890834\">8890834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo; <i>N Eng J Med</i>, 2005, 352(18):1899-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/15872205/pubmed\" target=\"_blank\" id=\"15872205\">15872205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo; <i>BMJ</i>, 1998, 317(7160):713-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/9732338/pubmed\" target=\"_blank\" id=\"9732338\">9732338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo; <i>Clin Pharmacokinetics</i>, 1988, 15(4):254-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/3191648/pubmed\" target=\"_blank\" id=\"3191648\">3191648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong DG, Spence JD, Lamki L, et al, &ldquo;Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics,&rdquo; <i>Lancet</i>, 1986, 1(8488):997-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/2871333 /pubmed\" target=\"_blank\" id=\"2871333 \">2871333 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo; <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acebutolol-drug-information/abstract-text/7911769 /pubmed\" target=\"_blank\" id=\"7911769 \">7911769 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9233 Version 179.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F129226\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F129227\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F129265\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F129230\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F129231\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F129232\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F129233\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F129199\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F129183\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23610278\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F129203\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F129202\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720646\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F129272\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F129190\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F129206\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F129187\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F129260\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F129192\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F129221\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F129195\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F129209\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F129210\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F129211\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F129197\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F129186\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F129205\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F129208\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F129212\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9233|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acebutolol-patient-drug-information\" class=\"drug drug_patient\">Acebutolol: Patient drug information</a></li></ul></div></div>","javascript":null}